Measuring Severity and Flare-Up Risk in Bronchiectasis Not Caused by Cystic Fibrosis
Follows adults with bronchiectasis for 12 months to predict flare-ups and severity.
Plain-language title generated from the registry record
Registry title: BASE: Bronchiectasis Severity and Exacerbation Risk Study
Key facts
- Where
- Asyut, EgyptSee the site
AI summary: who the study is looking for
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for adults with non-cystic fibrosis bronchiectasis, a long-term lung disease. People follow their usual care and are followed for 12 months.
- Age
- 18 years or older
- Sex
- Women and men can join
- Disease stage
- Non-cystic fibrosis bronchiectasis confirmed by clinical assessment and a high-resolution CT scan (HRCT). People who are stable or routinely assessed can join.
Main reasons for not taking part
- Cystic fibrosis-related bronchiectasis
- Bronchiectasis caused by advanced fibrotic interstitial lung disease as the main lung diagnosis
- Active pulmonary tuberculosis
- Active nontuberculous mycobacterial lung disease that needs specific treatment
- Active cancer or terminal illness expected to prevent 12-month follow-up
Read by machine on 12 November 2026.
Where in Egypt
- Assiut University- Faculty of MedicineAsyut, EgyptContact: Ahmad M Shaddad, MDTaking people
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorTrial details
- Who runs it
- Assiut University
- Trial code
- NCT07599839
- Record updated
- 20 May 2026
- Original description
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic airway disease characterized by permanent bronchial dilatation, impaired mucus clearance, recurrent infection, airway inflammation, and repeated exacerbations. Existing bronchiectasis severity tools are clinically useful, but many depend on prior exacerbation history, hospitalization history, subjective symptom assessment, or culture-based microbiological classification.Read full original descriptionShow less
BASE: Bronchiectasis Assessment of Severity and Exacerbations for Baseline Severity Classification and One-Year Exacerbation Risk Prediction in Non-Cystic Fibrosis Bronchiectasis
Non-cystic fibrosis bronchiectasis (NCFB) is a chronic airway disease characterized by permanent bronchial dilatation, impaired mucus clearance, recurrent infection, airway inflammation, and repeated exacerbations. Existing bronchiectasis severity tools are clinically useful, but many depend on prior exacerbation history, hospitalization history, subjective symptom assessment, or culture-based microbiological classification.
This prospective observational cohort study aims to develop and validate the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework. BASE is designed to classify current bronchiectasis severity and predict 12-month exacerbation risk using objective baseline functional, radiological, oxygenation, and inflammatory variables. Detailed methodological specifications, including variable definitions, scoring architecture, endpoint hierarchy, development-validation governance, and analytical integrity rules, are archived in a restricted-access Zenodo record: https://doi.org/10.5281/zenodo.20143505
.
Participants will receive routine clinical care, and no treatment or intervention will be assigned by the study protocol. Patients will be followed for 12 months to record bronchiectasis exacerbations, hospitalization, lung-function change, inflammatory marker change, and clinical outcomes. The Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework includes two linked baseline models: the BASE Severity model (BASE-S) for current bronchiectasis severity classification and the BASE Prognostic model (BASE-P) for prediction of 12-month exacerbation risk. Both models will be derived in the development cohort and applied unchanged to the validation cohort.
Inclusion: Adult patients aged 18 years or older; Diagnosis of non-cystic fibrosis bronchiectasis (NCFB) based on clinical assessment and high-resolution computed tomography (HRCT); Clinically stable or routinely assessed patients with non-cystic fibrosis bronchiectasis (NCFB) eligible for baseline severity and risk assessment; Patients attending outpatient clinic, inpatient ward, or respiratory follow-up services at Assiut University Hospitals during the study enrollment period; Patients suitable for prospective baseline assessment using the Bronchiectasis Assessment of Severity and Exacerbations (BASE) framework; Ability to undergo routine clinical, functional, radiological, oxygenation, and inflammatory assessment according to the study protocol; Ability to complete planned 12-month follow-up for bronchiectasis exacerbation and outcome assessment; Written informed consent obtained from the patient or legal representative.
Exclusion: Recent major thoracic surgery or acute thoracic trauma interfering with baseline respiratory assessment; Traction bronchiectasis due to advanced fibrotic interstitial lung disease as the dominant respiratory diagnosis; Active pulmonary tuberculosis at enrollment; Active nontuberculous mycobacterial pulmonary disease requiring specific treatment at enrollment; Active malignancy or terminal non-respiratory illness expected to prevent 12-month follow-up; Acute life-threatening illness preventing safe enrollment or baseline assessment; Cystic fibrosis-related bronchiectasis; Inability to complete the required baseline or Bronchiectasis Assessment of Severity and Exacerbations (BASE) assessment according to the study protocol; Inability or unwillingness to complete planned 12-month follow-up; Refusal to participate.